|
| |
Dividend, Bonus, Split & Consolidation Hints : Click here to modify the Visible Columns.
  Investeye Disposed most of the lots as EPF is gradually disposed this counter.. Wait for next wave.. 23/04/2019 9:56 AM Investeye Disposed all DPharma and bank on Pharma. In general, EPF disposed more than acquired.. 23/04/2019 4:40 PM  YAPSS Day 81 of Fundamental Daily, YAPSS will be covering Duopharma Biotech Berhad's fundamental via a short animated video. I hope it helps and please enjoy the video, see ya! #YAPSS #FundamentalDaily #DuopharmaBiotechBerhad Click the on the link to find out more: https://youtu.be/wKtLhzvZy_c 25/05/2019 9:28 AM factorrumour price has been flat for quite some time already, is it a good time to enter? 25/06/2019 4:08 PM NewbieTradingChannel Dpharma 7/7/2019 now it is on a symmetrical triangle ... breaking 1.3900 can target 1.440. 07/07/2019 1:25 PM k3nthiew https://www.reuters.com/article/us-duopharma-btech-malaysia/malaysias-duopharma-talks-deals-with-trade-war-hit-chinese-firms-idUSKCN1UW0E4 06/08/2019 4:11 PM k3nthiew KUALA LUMPUR (Reuters) - Duopharma Biotech (DUOP.KL), Malaysia’s largest generic drugmaker, is in talks with two Chinese consumer healthcare companies for expansion of their production base in Southeast Asia and a potential stake sale, its managing director said. During an interview with Reuters, Duopharma Managing Director Leonard Ariff bin Abdul Shatar declined to name the companies as the discussions were ongoing. However, he said both “reasonably big” companies were listed in China with an annual revenue of more than $1 billion each. The Chinese companies, one based in Shanghai and the other in Beijing, had asked Kuala Lumpur’s Duopharma if it would be able to contract-manufacture for them. They have also discussed buying a stake in Duopharma, Leonard said. “They have manufacturing bases currently in China, supplying to the United States. These are guys whom I would not have expected to see in this part of the world, but for the trade war,” he said. Duopharma, which has a market valuation of about $220 million, was open to a stake sale of up to 10% in the company, Leonard said, adding that if a deal was finalised, the Malaysian firm will apply to register with the U.S. Food and Drug Administration. “There is a famous Malay saying: when two elephants fight, the ants die. But what we see here is absolutely the opposite. This has come as a bit of a surprise,” he said. Dented by higher U.S. tariffs, Chinese companies are seeking partners to partly shift their supply chain to Southeast Asian countries such as Vietnam, Malaysia and Indonesia, analysts and Malaysian government officials said. In the first quarter of 2019, Southeast Asia’s third-biggest economy attracted foreign investment of more than $7 billion – a 73% surge from a year earlier. The Malaysian government and its trade agencies are sending their representatives to China and other countries, organizing seminars and signing agreements of cooperation. Late last month, the China ambassador to Malaysia confirmed the high level of Chinese interest in its traditional trade partner. 06/08/2019 4:12 PM Jason Good fundamental and aggressive management. This counter is worth to hold for long term investment. 06/08/2019 5:20 PM factorrumour only super good quarter result can help it push to all time high and new record 23/08/2019 12:07 AM kalofarmako It's going up time to buy ! Come on gaiss. https://klse.i3investor.com/blogs/MYpharmaceuticalnews/221505.jsp 26/08/2019 10:52 AM kalofarmako Pharmaniaga’s focus on non-concession ops seen to boost profit https://www.klsescreener.com/v2/news/view/572140 28/08/2019 9:59 AM Jason among all the other healthcare counter, only this one is on uptrend. Phamaniage revenue and profit is inconsistent and poor cash flow, no way to compare to duopharma. 28/08/2019 11:54 AM kalofarmako Morning! Something good to read in the morning. "High time to decide on concession issue" Read more: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/222426.jsp 30/08/2019 9:10 AM kalofarmako WOW!! The positive long-term outlook for Pharmaniaga Read more: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/223457.jsp 05/09/2019 1:09 PM kalofarmako DHM explained that Pharmaniaga is only responsible for the logistics of supplying drugs to government health facilities, rather than the supply itself. Check out here: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/224313.jsp 11/09/2019 10:56 AM  rajachulan I had stopped buying any stock which dealing with gomen... many months ago... after i have seen how gomen play construction sector... gdluck buying stock dealing with gomen... 11/09/2019 11:00 AM kalofarmako “The big problem is price control, not Pharmaniaga,” says MyCC Social activist Lim Mah Hui, one of the conductors of the MyCC study, said Pharmaniaga did not have a monopoly over supply but a virtual monopoly over logistics. Check out: https://klse.i3investor.com/blogs/MYpharmaceuticalnews/224759.jsp 13/09/2019 9:52 AM rajachulan no doubt... healthcare and insurance are two industries APAC to grow next few decade... however... if the govt !@#$%^&*()... then !@#$%^&*() 13/09/2019 10:07 AM soccerking82 what is mean by Interim Dividend (with Dividend Re-Investment Plan) ? It is by default go to dividend re-investment plan or we need to fill in some form ? Actually i more prefer receive dividend, and i don't want have odd lot in my account. 03/10/2019 5:07 PM kalofarmako The public need to understand that Pharmaniaga's role as a concessionaire and not immediately liken it to a monopoly. Shared some thoughts in this article (https://klse.i3investor.com/blogs/MYpharmaceuticalnews/228733.jsp). Though it could use a bit more context but hope this can get the conversation going. Source: http://read.focusmalaysia.my/ePaper/xml_epaper/Focus/05_10_2019/pla_1_Standard/xml_arts/art_52429.htm 07/10/2019 4:23 PM  |
|
